# A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

> **NCT00423306** · PHASE2 · UNKNOWN · sponsor: **Alaunos Therapeutics** · enrollment: 15 (actual)

## Conditions studied

- HEPATOCELLULAR CARCINOMA

## Interventions

- **DRUG:** Darinaparsin

## Key facts

- **NCT ID:** NCT00423306
- **Lead sponsor:** Alaunos Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-01
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423306, "A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00423306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*